AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 21 min read$EMMA

LEE WILLIS C purchased $18K of EMMA (indirect holdings)

LEE WILLIS C (CEO) purchased 530,767 indirectly-held shares of Emmaus Life Sciences, Inc. (EMMA) at an average of $0.03 ($0.01–$0.06) across 6 trades over 2025-05-30 to 2026-08-31.

Original reporting
SEC EDGAR · LEE WILLIS C
Published Sep 2, 2026, 7:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 7:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EMMA
Neutral
high confidence
Mentioned
$EMMA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EMMANeutralLow
01

Why it matters

The purchase is modest and unlikely to influence market perception.

02

Market read

Limited relevance; primarily of interest to existing shareholders.

03

What to watch

Potential upcoming corporate events not disclosed could change significance.

Relevance 3/10Novelty 3/10Timing: Filed Sep 2 2026

Background

Form 4 filing discloses insider transactions; EMMA is a biotech micro‑cap.

Company-level read

Ticker impact

$EMMANeutralHigh confidence
Context

CEO Lee Willis purchased $18,126 of EMMA shares via open‑market trades.

Expected impact

No significant price change expected.

Evidence & confidence

Purchase size is trivial relative to market cap and trading volume.

Market effects

Sector

None; insider activity does not affect sector outlook.

Regional

None; micro‑cap transaction limited to US market.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; monitor for follow‑on purchases.

Key entities

  • Person
    Lee Willis

    CEO of Emmaus Life Sciences, Inc.

  • Company
    Emmaus Life Sciences, Inc.

    Biotech firm trading under ticker EMMA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EMMA insider trading history →

Related articles

AUG 14
$EMMAMed

Emmaus Life Sciences, Inc. (EMMA): Results of Operations and Financial Condition

Emmaus Life Sciences, Inc. (EMMA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Emmaus Life Sciences Reports Quarterly Financial Results Torrance CA, August 14, 2026 - Emmaus Life Sciences, Inc. (OTCQB: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial conditi

SEC EDGAR 8-K6 min
SEP 18
$DELLLow

Silver Lake Partners IV, L.P. (Durban Egon) sold $29.2M of DELL (indirect holdings)

Silver Lake Partners IV, L.P. sold 51,494 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $567.88 ($561.56–$573.28, $29.24M total) across 13 trades on 2026-09-16. Filed jointly with Silver Lake Technology Associates IV, L.P. (Director), SLTA IV (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).

SEC EDGAR1 min